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Abstract
Introduction: People who inject drugs (PWID) in Ukraine have high prevalences of HIV and hepatitis C (HCV). Since the turn
of the century, various organizations have funded non-governmental organizations (NGOs) in Ukraine to provide PWID with
needles and syringes, condoms, HIV and HCV testing, and improve linkage to opioid agonist therapy (OAT) and HIV treatment.
We investigated whether contact with these NGOs was associated with improved HIV prevention and treatment outcomes
among PWID.
Methods: Five rounds of respondent-driven sampled integrated bio-behavioural survey data (2009 [N = 3962], 2011
[N = 9069], 2013 [N = 9502], 2015 [N = 9405], and 2017 [N = 10076]) among PWID in Ukraine (including HIV/HCV testing
and questionnaires) were analysed using mixed-effect logistic regression models (mixed-effects: city, year). These regression
models assessed associations between being an NGO client and various behavioural, OAT, HIV testing and HIV treatment out-
comes, adjusting for demographic characteristics (age, gender, lifetime imprisonment, registration in a drug abuse clinic, educa-
tion level). We also assessed associations between being an NGO client and being HIV positive or HCV positive, likewise
adjusting for demographic characteristics (as above).
Results: NGO clients were more likely to have received HIV testing ever (adjusted odds ratio [aOR] 5.37, 95% confidence
interval [95% CI]: 4.97 to 5.80) or in the last year (aOR 3.37, 95% CI: 3.20 to 3.54), to have used condoms at last sexual
intercourse (aOR 1.37, 95% CI: 1.30 to 1.44) and sterile needles at last injection (aOR 1.37, 95% CI: 1.20 to 1.56), to be cur-
rently (aOR 4.19, 95% CI: 3.48 to 5.05) or ever (aOR 2.52, 95% CI: 2.32 to 2.74) on OAT, and to have received syringes
(aOR 109.89, 95% CI: 99.26 to 121.66) or condoms (aOR 54.39, 95% CI: 50.17 to 58.96) in the last year. PWID who were
HIV positive (aOR 1.40, 95% CI: 1.33 to 1.48) or HCV positive (aOR 1.57, 95% CI: 1.49 to 1.65) were more likely to have
contact with NGOs, with HIV positive PWID in contact with NGOs being more likely to be registered at AIDS centres (aOR
2.34, 95% CI: 1.88 to 2.92) and to be on antiretroviral therapy (aOR 1.60, 95% CI: 1.40 to 1.83).
Conclusions: Contact with PWID targeted NGOs in Ukraine is associated with consistently better preventive, HIV testing and
HIV treatment outcomes, suggesting a beneficial impact of harm reduction NGO programming.
Keywords: Ukraine; harm reduction; prevention; HIV; hepatitis C virus; NGO
Additional information may be found under the Supporting Information tab for this article.
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1 | INTRODUCTION
Globally, there are an estimated 15 million people who inject
drugs (PWID), amongst whom there is a high prevalence of
HIV (17.8%) and exposure to hepatitis C virus (HCV) infection
(52.3%), primarily due to bloodborne transmission through
unsterile injections [1,2]. Estimates of the global disease bur-
den of HIV due to injecting drug use (IDU) are low (4% glob-
ally [3]), but high in some regions, whereas for HCV this
figure is around 40% for both disease burden [3] and inci-
dence [4]. Eastern Europe and Central Asia is the only region
where the number of HIV infections and HIV-related deaths
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are increasing [5], with this region also having the highest gen-
eral population prevalence of HCV [6]. Ukraine has the second
biggest epidemic of both HIV and HCV in the region and in
Europe overall [6-8]. In Ukraine, the prevalence of IDU among
adults (approximately 1%) is higher than the global average
(approximately 0.3%) [1], with an estimated 50% and 80% of
the HIV and HCV burdens, respectively, being due to IDU [3].
Due to their high prevalence and incidence of HIV and HCV,
PWID, both globally and in Ukraine, require targeted interven-
tions to reduce transmission levels and to provide disease care
and treatment. These measures include needle and syringe pro-
vision (NSP), opioid agonist therapy (OAT), condom distribution,
curative treatment for HCV, and antiretroviral therapy (ART)
for HIV. Evidence shows high coverage of NSP and OAT are
effective at reducing HIV and HCV acquisition among PWID
[9,10]. Curative treatment for HCV can also reduce HCV trans-
mission [11], whereas ART can effectively halt HIV transmission
by reducing viral loads to undetectable levels [12]. Initiating
HIV positive PWID onto ART requires them to be diagnosed
and linked to care, which requires a high coverage of testing.
There has been progress combating HIV in Ukraine, with
UNAIDS reporting AIDS-related deaths halving from 14,000
to 7,900 over 2010 to 2015 [13]. Most HIV treatment and
prevention funding currently comes from the Global Fund to
fight AIDS, tuberculosis, and malaria, with 547 million US dol-
lars (USD) disbursed since 2003. Most funds have gone to
non-governmental organizations (NGOs) such as the Alliance
for Public Health (APH) and 100% Life [14]. These NGOs aim
to reduce the epidemics of HIV, hepatitis and tuberculosis
among the most vulnerable populations in Ukraine, including
PWID, men who have sex with men and sex workers. In coop-
eration with other organizations, they distribute condoms and
needles/syringes, provide HIV and HCV testing and coun-
selling, and encourage linkage to ART and OAT. The Ukrainian
government provides ART in AIDS centres and runs OAT pro-
grammes. Recently, global funders have reduced funds to mid-
dle-income country settings based on the assumption that
their governments can and should fund interventions for HIV,
HCV and tuberculosis. Because of this, funding for Ukraine
from the Global Fund is decreasing, with the latest grant for
Ukraine supporting the transition of prevention services to
the government [15]. There are concerns that this could
reduce funding for HIV, exacerbated by a recent economic cri-
sis and war with Russia [16], raising concerns of possible
reductions in services for key populations.
APH has undertaken seven repeated nationwide cross-sec-
tional integrated bio-behavioural surveys (IBBS) over 2004 to
2017. The primary aim of this study was to use data from sur-
veys undertaken between 2009 to 2017 to determine
whether being a client of an NGO is associated with improved
HIV and HCV prevention and treatment outcomes and related
injecting- or sexual-risk behaviours among PWID in Ukraine.
2 | METHODS
2.1 | Setting and sample
Data came from five nationwide IBBS among PWID in Ukraine
covering the years 2009, 2011, 2013, 2015 and 2017 [17-20].
Full details of the sampling methodology are given in each sur-
vey report (the 2017 report is not yet available, but methods
are similar). In brief, the IBBS used respondent-driven sampling
(RDS) to recruit PWID. Eligible participants had injected drugs
in the last 30 days, were aged ≥14 years and resided in a par-
ticipating city. They needed to give consent to being surveyed,
provide a dried blood spot sample, and agree to HIV and/or
HCV testing. A person could partake in multiple survey rounds.
The number of initial respondents (seeds) varied between 2
and 6 for different cities and years depending on the planned
sample size. These seeds had to be aged under 26 and be HIV
negative. They were selected to cover a range of parameters
regarding gender, age, drug use and harm reduction contact.
Table S1 presents the number of overall participants in each
city for each survey round, and their regions. There were 31
cities included, which covered all of Ukraine’s 27 regions, and
so should be representative of Ukraine. Fifteen cities were
included in all five rounds, whereas 11 were included in four
rounds. The surveys were carried out in various locations,
mostly rented office blocks, AIDS centres and sometimes
offices of organizations providing services to PWID. The sur-
veys were often carried out by NGOs.
2.2 | Measures
Questions were asked about demographic characteristics,
injecting and sexual behaviours, harm reduction intervention
contact and outcomes, recent contact and duration of contact
with NGOs, HIV/HCV testing history, self-reported HIV/HCV
diagnosis status and HIV treatment uptake. The questions
included in each survey were similar across rounds with some
minor differences, and, in some years, particular questions
were added or excluded. Our analyses focus on questions that
are comparable across all rounds. Data regarding whether
someone is a client of an NGO was obtained through self-re-
port, using the question: “Are you a client of any non-govern-
mental organization (have a card or individual code), that
provides prevention services for injection drug users?”.
Further details of the questions can be found in Table S2.
HIV and HCV testing were also performed in each survey
(except HCV testing in 2009). Rapid tests for HIV and HCV
were used to determine a respondent’s status.
2.3 | Analyses
We chose not to use RDS-weights in the main analysis due to
a lack of consensus around their use for regression models
[21], particularly when RDS surveys across multiple sites are
combined. However, we present RDS-weighted characteristics
for comparison in sensitivity analyses.
2.4 | Comparing PWID by NGO client status
Tests for differences in behaviours and preventive outcomes
by current NGO client status were assessed by either v2 tests
or t-tests, depending on whether the variable was binary or
continuous.
2.5 | Characteristics associated with being an NGO
client
We tested for general non-intervention related characteristics
associated with being an NGO client (vs. not), using mixed-
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effect logistic regression with year and city as crossed random
effects.
In unadjusted and adjusted analyses, we investigated
whether testing HIV positive (vs. negative), testing HCV anti-
body positive (vs. negative), age (years), female sex (vs. male),
having ever been imprisoned (vs. not), being registered in a
drug abuse clinic (vs. not) and education level (categorical: see
supplementary materials) were associated with being an NGO
client. For 2009, information on imprisonment was unavailable
so data from this year were not included in these models. In a
sensitivity analysis, we removed imprisonment and HCV from
the model and included the 2009 survey data.
2.6 | Associations between being an NGO client
and intervention-related outcomes
To assess for associations between NGO client status and
various intervention-related outcomes around HIV/HCV and
their transmission, we used mixed-effect logistic regression
models with year and city as crossed mixed-effects. In mixed-
effects models the adjusted odds ratios should be interpreted
as holding all other variables in the model constant, as well as
the random effects for city and year. The use of mixed-effects
models was to account for variation in levels of service provi-
sion and epidemiological characteristics between cities and
years (and differences between years within cities), without
explicitly modelling this. Unadjusted and adjusted associations
of the outcomes with NGO client status, age, female sex, hav-
ing ever been imprisoned, being registered in a drug abuse
clinic and education level were assessed.
2.7 | NGO client duration
Mixed-effect logistic regression models with the same struc-
ture were used to assess trends between duration of NGO
client status (assessed as a continuous variable in years among
those with known duration) and various risk behaviour and
intervention outcomes. These models were also adjusted for
age, except the model with age as the outcome (a mixed-effect
linear regression model). NGO client duration data were
unavailable for 2009 so this survey was omitted from these
analyses.
2.8 | Use of services by PWID
Data from the earliest (2011) and most recent survey (2017)
with self-reported use of HIV services were compared over
the two years. The outcomes compared were the number of
PWID testing HIV+, the number of these that self-reported
HIV+, the number reporting being registered at an AIDS cen-
tre, and the number reporting that they receive ART. Tests
for differences in the use of services by whether PWID were
NGO clients or not were assessed using v2 tests.
2.9 | Trends over time
Trend tests for variables across multiple survey years were
performed using logistic or linear regression, depending on
whether the outcome variable was binary or continuous, with
cluster-robust standard errors being used for clustering by
city.
2.10 | Ethical approval
The surveys underwent examination by the Committee of
Medical Ethics at the Institute of Epidemiology and Infectious
Diseases of the Ukrainian Academy of Medical Sciences.
Informed consent was obtained from all study participants.
3 | RESULTS
The number of PWID surveyed in each IBBS were 3963
(2009), 9069 (2011), 9502 (2013), 9405 (2015) and 10,076
(2017). Table shows characteristics and behaviours of the
PWID surveyed in each year and tests for trends. Across all
surveys, around one-third of PWID surveyed self-reported as
NGO clients, which was stable over the years. A sensitivity
analysis using RDS-weighted estimates (Table S3) gave similar
results.
3.1 | Comparing PWID by NGO client status
Table 2 compares the characteristics and behaviours of NGO/
non-NGO clients across survey years and overall. All variables
analysed showed differences between these two groups. In
these analyses, NGO clients were more likely to be female,
older, and to have completed secondary education. They
tended to inject more frequently, were more likely to primarily
inject opioids and to have ever been imprisoned, but less likely
to have been imprisoned in the last year. NGO clients were
more likely to be registered in a drug abuse clinic and to have
ever been or currently on OAT. They were more likely to have
received syringes or condoms in the last year and conversely
were less likely to have bought syringes or condoms in the
last month. NGO clients were more likely to have either
received or bought syringes in the last year, which was also
the case for condoms. NGO clients were also more likely to
have used condoms for their last sexual intercourse and were
more likely to have used a sterile needle for their last injec-
tion. For HIV, they were more likely to have ever been tested
in the last year or ever. A greater proportion of NGO clients
self-reported as HIV+ (20.4% vs. 7.0%) and tested HIV+
(29.2% vs. 17.8%) or HCV+ (64.5% vs. 48.1%). Of those self-
reporting HIV+, a greater proportion of NGO clients were
registered at an AIDS centre and, of these, a greater propor-
tion reported receiving ART. Mean monthly income in 2017
(when data were available) for NGO clients was lower than
for non-NGO clients, 4,663 vs. 5,219 Ukrainian hryvnia
(approximately 190.46 vs. approximately 213.17 USD on 23
January 2020). Table S4 shows categorized education-level
stratified by year and NGO client status.
3.2 | Characteristics associated with being an NGO
client
Table 3 shows unadjusted and adjusted odds ratios of being
an NGO client for various demographic characteristics. PWID
testing HIV+ and HCV+ were more likely to be NGO clients.
PWID that were female, that had ever been imprisoned, that
were registered in a drug abuse clinic, or had higher educa-
tion were more likely to be NGO clients, whereas PWID
released from prison within the last 12 months were less
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likely to be NGO clients. In the sensitivity analysis (Table S5)
removing the ever imprisoned and HCV variables and includ-
ing the 2009 survey data, produced similar results.
3.3 | Associations between being an NGO client
and intervention-related outcomes
The differences between NGO and non-NGO clients seen in
Table 2 are borne out in Table 4 and Figure 1. In both unad-
justed and adjusted regression analyses, NGO clients were
more likely to have ever been tested for HIV, to have been
tested in the last year, to have used a sterile needle for their
last injection, to have used a condom for their last intercourse,
to currently or have ever been on OAT, to be registered in a
drug abuse clinic, to be registered at an AIDS centre, and to
self-report being on ART (among those self-reporting as
HIV+), and to test HIV+ or HCV+. NGO clients were more
likely than non-clients to have received syringes and condoms
in the last year, but were less likely to have bought syringes
or condoms in the last month. When combining these mea-
sures, NGO clients were more likely to have received or
bought syringes, with the same result for condoms. Among
the HIV-negative PWID, NGO clients were more likely to have
been tested for HIV in the last year (adjusted odds ratio:
3.96, 95% confidence interval: 3.73 to 4.19) than non-NGO
clients.
3.4 | NGO client duration
Trends in characteristics and behaviours by NGO client dura-
tion (per year increase among NGO clients) are shown in
Table 5, with PWID that have been NGO clients for longer
tending to be older, more likely to have ever been imprisoned
or tested for HIV, and less likely to have bought syringes or
condoms in the last month. The more experienced NGO
clients were also more likely to be registered in a drug abuse
clinic, to have ever been on OAT or to currently be on OAT
and were more likely to be HIV+ or HCV+. Among those self-
reporting as HIV+, the longer someone was an NGO client
the more likely they were to be registered at an AIDS centre
or to be on ART.
3.5 | Use of services by PWID
Figure 2 shows the self-reported use of HIV services in 2011
and 2017 for those testing HIV+. For both 2011 and 2017,
better outcomes were seen for each outcome among NGO cli-
ents (p < 0.001). A higher proportion of NGO clients reported
being aware of their HIV+ status, more were registered at an
AIDS centre, and more self-reported being on ART. The dis-
parities between the outcomes for the NGO and non-NGO
clients increased from 2011 to 2017.
4 | DISCUSSION
In this analysis, data from five IBBS in Ukraine spanning 2009
to 2017 showed that PWID in contact with harm reduction
NGOs obtained more condoms and new injecting equipment,
were more likely to use sterile needles and condoms, and
were more likely to be on OAT. These better outcomes were
seen despite NGO clients being more marginalized in terms
of ever being imprisoned, being poorer, and injecting more
frequently. They were also more likely to be HCV positive or
HIV positive, with HIV-positive NGO clients being more
engaged in using HIV services than non-NGO clients. Many of
these associations became stronger with longer NGO client
duration, which could be due to a dose–response relationship
or possibly survivor bias – further research on this topic is
required.
Table 3. Unadjusted and adjusted odds ratios (with 95% confidence intervals) from mixed-effect logistic regressiona, of being an
NGO client for various demographic characteristics
Variable Unadjusted OR (95% CI) p-value
Adjusted OR (95% CI)
[N = 37,845] p-value
HIV+ [N = 38,053] 2.18 (2.06, 2.30) <0.001 1.48 (1.39, 1.57) <0.001
Hepatitis C virus (HCV) antibody+ [N = 38,052] 2.30 (2.19, 2.42) <0.001 1.72 (1.63, 1.81) <0.001
Age (years) [N = 38,053] 1.03 (1.02, 1.03) <0.001 1.00 (1.00, 1.01) 0.151
Female [N = 37,920] 1.32 (1.25, 1.40) <0.001 1.43 (1.35, 1.51) <0.001
Ever imprisoned [N = 37,917] 1.68 (1.61, 1.76) <0.001 1.28 (1.21, 1.36) <0.001
Imprisoned in the last 12 months [N = 38,053] 0.93 (0.84, 1.02) 0.116 0.66 (0.59, 0.73) <0.001
Registered in a drug abuse clinic [N = 38,053] 3.24 (3.08, 3.41) <0.001 2.61 (2.48, 2.76) <0.001
Education [N = 37,848]
Primary education 1 1
Incomplete secondary education 0.87 (0.75, 1.01) 0.062 0.82 (0.70, 0.95) 0.011
Complete secondary education 0.85 (0.74, 0.98) 0.024 0.81 (0.70, 0.94) 0.006
Basic higher education 0.92 (0.79, 1.07) 0.260 0.94 (0.80, 1.10) 0.415
Complete higher education 0.93 (0.79, 1.09) 0.376 0.98 (0.83, 1.16) 0.845
CI, confidence interval; OR, odds ratio.
aWith survey year and city as the crossed random effects – 2009 was excluded for this analysis due to missing data for HCV and ever imprisoned.
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Data suggested the use of services by PWID improved over
time, with the percentage of PWID ever tested for HIV
increasing by half and the percentage of HIV-positive PWID
on ART doubling from 2009/2011 to 2017. The differences in
outcomes between NGO and non-NGO clients also increased
between 2011 and 2017, possibly as NGOs became more
effective. These results should be considered in light of
increases in ART coverage over this time, making interpreta-
tion of this trend complicated.
4.1 | Comparison with other literature
Other studies in Ukraine have considered the HIV cascade of
care and prevalence trends. An analysis of 2015 IBBS data
among HIV-positive PWID also found evidence that NGO-sta-
tus was positively associated with self-reported registration at
an AIDS centre and receiving ART [22]. Otherwise, a study
from 2011 to 2014 using intervention monitoring and evalua-
tion data found that harm reduction coverage (receiving more
syringes and condoms) was associated with decreased HIV
acquisition risk [23], adding to our findings that harm reduc-
tion coverage is linked to improvements in risk behaviours
and coverage of OAT and ART.
Notably, considering the high imprisonment rates among
PWID in this analysis, other studies in Ukraine have
highlighted the importance of the prison setting in driving the
HIV and HCV epidemics [24-26], emphasizing the importance
of controlling for imprisonment whenever possible. A mod-
elling study found that scaling up OAT in Ukraine from the
current levels (approximately 2.7% of PWID) to 20% would
reduce new HIV infections by 56% and deaths by 49% over
10 years [27]. Lastly, few studies have focussed on HCV in
Ukraine, with two finding similarly high HCV prevalence
among PWID (approximately 60%) [28,29].
4.2 | Strengths and limitations
The strengths of our analyses include using multiple national
level IBBS with large sample sizes, spanning many years that
ask comparable questions over the surveys. The questions
asked spanned diverse topics allowing examination of many
outcomes, with our findings consistently suggesting that harm
reduction contact has multiple benefits. Importantly, the use
of a national IBBS also means the results should be generaliz-
able to the national level.
While most questions were the same or similar across
years, some questions changed or were unavailable for partic-
ular years, especially 2009. Also, while most cities/regions
were sampled in all IBBS, some were omitted for certain
rounds. HIV viral load was only tested among a subsample of
Figure 1. Adjusted* odds ratios (with 95% confidence intervals) for various outcomes from being an NGO client compared to not being an
NGO client, using mixed-effect logistic regression.*Adjusted for age, gender, whether they had ever been imprisoned, whether they are reg-
istered at a drug clinic, and education level. Models have year and city as mixed-effects except for the HCV model that only has year as a
mixed-effect. The model with being registered in a drug abuse clinic as an outcome did not adjust for this variable.
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the HIV-positive PWID (to help estimate HIV incidence) in
later surveys so could not be used as a biological marker of
successful ART uptake. The analyses were limited to looking at
associations rather than causation. While the results for HIV
and HCV infection exposure were based on biological testing,
all other behaviours and uptake of interventions were based
on self-reported data. These could be affected by a range of
biases, such as recall bias, particularly as many questions ask
about behaviours over a long timeframe. Social desirability
bias could lead to an overestimation of harm reduction prac-
tices and an underestimation of risky practices. Despite this, it
is uncertain whether there would be differential bias between
NGO clients and non-clients. Another potential limitation is
that RDS was used to enrol participants and sample charac-
teristics may change with each survey, although our results
are similar with and without RDS weighting. Additionally, the
quality of data captured may have improved with each round
of the survey due to an increase in expertise of groups (often
NGOs) carrying out the survey, which frequently stayed the
same across years. However, once again, it remains unclear
whether this would differentially affect NGO and non-NGO
clients. There is also the possibility that the question used to
determine our main analysis measure, whether or not some-
one was a client of an NGO, could have been misunderstood
by some participants, with some having had contact with
NGOs but not being clients. This may mean our results are
conservative because NGOs may also have positive outcomes
among non-clients. Carrying out some of the surveys in the
offices of organizations that provide services for PWID could
also have created information bias where PWID were aware
that those carrying out the surveys were linked to NGOs and
so preferred to report behaviours that were deemed desirable
to the interviewers. Unfortunately, data on survey setting are
not available so we could not examine this effect.
Table 5. Outcomes linked to bloodborne viruses and their transmission, stratified by duration as a client of a non-governmental
organization (NGO), with a test for trend by duration of NGO contact (per year increase)a
Outcome
NGO client duration







5 years 6+ years Unknown
[N = 5495] [N = 3651] [N = 1747] [N = 1581] [N = 25,579]
Age (years) 33.3 35.5 38.4 34.7 1.86 (1.77, 1.96) 33.6
Ever imprisoned 40.1% 46.3% 58.7% 45.2% 1.04 (1.03, 1.06) 33.7%
Syringes received year 95.5% 96.4% 94.4% 92.9% 0.98 (0.94, 1.01) 20.4%
Condoms received year 92.1% 92.6% 89.2% 87.9% 0.98 (0.96, 1.01) 19.6%
Bought syringes last year 51.7% 45.4% 53.0% 61.9% 0.98 (0.96, 0.99) 88.4%
Bought condoms last year 9.7% 7.3% 7.0% 5.0% 0.96 (0.93, 0.99) 25.4%
Last needle sterile 97.1% 97.9% 97.0% 95.5% 1.00 (0.95, 1.04) 95.4%
Condom last intercourse (among those
who had had sex)
58.0% 57.7% 51.1% 54.6% 0.99 (0.98, 1.01) 48.9%
HIV test ever 90.5% 95.7% 97.5% 88.8% 1.22 (1.17, 1.27) 64.8%
HIV test last year 62.0% 56.8% 61.2% 65.0% 1.00 (0.99, 1.02) 29.5%
Ever OAT (Among primary opioid
injectors)
17.3% 22.5% 29.5% 15.9% 1.09 (1.07, 1.11) 6.5%
Current OAT (Among primary opioid
injectors)
10.5% 12.2% 15.3% 8.2% 1.08 (1.05, 1.11) 2.0%
Registered in a drug abuse clinic 42.2% 54.5% 65.3% 47.4% 1.12 (1.10, 1.14) 24.5%
Aware of HIV+ status (among those
testing HIV+)
60.5% 69.0% 81.5% 60.8% 1.10 (1.07, 1.13) 37.0%
Registered at AIDS centre (of self-
reported HIV+)
89.1% 91.9% 95.8% 89.8% 1.20 (1.10, 1.29) 79.5%
On ART (of self-report HIV+) 54.2% 58.2% 71.4% 62.2% 1.05 (1.01, 1.08) 46.0%
HIV+ 25.7% 29.4% 38.4% 29.2% 1.07 (1.05, 1.08) 17.5%
HCV+ 62.0% 64.0% 73.7% 63.8% 1.03 (1.01, 1.05) 48.1%
ART, antiretroviral therapy; CI, confidence intervals; HCV, hepatitis C virus; OAT, opiate agonist therapy; OR, odds ratio.
aTests performed using mixed-effects logistic regression modelling (linear for age as the outcome) among PWID that have a known duration as an
NGO client. This NGO client duration is included as an independent variable and year and city included as crossed mixed-effects respectively.
Models are also adjusted for age, except for the model with age as the outcome. Data from 2009 were omitted as information on NGO client
duration was missing, whereas only data were available for 2015 and 2017 for the current OAT outcome.




Ukraine has the second largest HIV and HCV epidemics in
Europe [7,8], for which IDU drives transmission [3,4]. NGOs
are a major provider of harm reduction services (including
needles, syringes and condoms) and testing of HIV and HCV
for PWID in Ukraine, whereas the government provides OAT
and ART. As of November 2019, support for core NGO ser-
vices will transition to government funding, with the Global
Fund only supporting extended prevention programmes, such
as naloxone. Our findings suggest harm reduction NGOs are
benefiting PWID in Ukraine by improving access to needles
and condoms, increasing OAT uptake, and improving all
aspects of the HIV continuum of care. Getting PWID onto
ART is crucial for halting the Ukrainian HIV epidemic, whereas
harm reduction interventions are crucial for reducing HIV and
HCV transmission [10,30]. For Ukraine to meet the UN’s 90-
90-90 HIV goals and elimination targets [31] or WHO’s HCV
elimination targets [32], government policy-makers need to
ensure sufficient funding continues for these interventions
since resources from the Global Fund have decreased [15].
The reduction in Global Fund support for harm reduction
NGOs comes during uncertain times for Ukraine. The country
has recently emerged from a recession and is still engaged in
a war with Russia, resulting in population migration [33],
including those with HIV and HCV [34]. This situation is exac-
erbated by the ongoing stigma borne by both PWID and peo-
ple living with HIV [35,36]. Additionally, the ongoing COVID-
19 pandemic will likely cause huge disruption to the Ukrainian
economy [37]. Against this backdrop of competing priorities
for the Ukrainian government, it is important that funding for
harm reduction programmes is not reduced, as they are asso-
ciated with public health benefits [10,23,30,38] and have been
shown to be cost-effective [39-41]. Indeed, an economic eval-
uation from 2018 suggested the role of NGOs should be
expanded to provide HIV care and treatment [41], something
that will start in October 2020 through support from the US
Centres for Disease Control and Prevention. It is important
that these services continue and are expanded because if
funding decreases, the HIV and HCV epidemics among PWID
could escalate to higher incidence [42], with further transmis-
sion bridging to other population groups.
Figure 2. Self-reported use of HIV services by HIV-positive PWID for 2011 (left) and 2017 (right), stratified by whether they are NGO cli-
ents or not, with tests for differences in proportions across groups.ART, antiretroviral therapy. NGO, non-governmental organization; Reg,
Registered at; SR, self-report.
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